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ABSTRACT
Background.With its convective component, hemodiaﬁltration
(HDF) provides better middle molecule clearance compared
with hemodialysis (HD) and is postulated to improve survival.
A previous analysis of Dialysis Outcomes and Practice Patterns
Study (DOPPS) data in 1998–2001 found lower mortality rates
for high replacement ﬂuid volume HDF versus HD.
Randomized controlled trials have not shown uniform survival
advantage for HDF; in secondary (non-randomized) analyses,
better outcomes were observed in patients receiving the highest
convection volumes.
Methods. In a ‘real-world’ setting, we analyzed patients on dia-
lysis >90days from seven European countries in DOPPS
Phases 4 and 5 (2009–15). Adjusted Cox regression was used to
study HDF (versus HD) and mortality, overall and by replace-
ment ﬂuid volume.
Results. Among 8567 eligible patients, 2012 (23%) were on
HDF, ranging from 42% in Sweden to 12% in Germany.
Median follow-up was 1.5 years during which 1988 patients
died. The adjusted mortality hazard ratio (95% conﬁdence
interval) was 1.14 (1.00–1.29) for any HDF versus HD and 1.08
(0.92–1.28) for HDF >20L replacement ﬂuid volume versus
HD. Similar results were found for cardiovascular and
infection-related mortality. In an additional analysis aiming to
avoid treatment-by-indication bias, we did not observe lower
mortality rates in facilities using more HDF (versus HD).
Conclusions. Our results do not support the notion that HDF
provides superior patient survival. Further trials designed to test
the effect of high-volume HDF (versus lower volume HDF ver-
sus HD) on clinical outcomes are needed to adequately inform
clinical practices.
Keywords: anemia, chronic kidney disease, dialysis, hemodia-
ﬁltration, high-ﬂux dialysis
INTRODUCTION
Due to its convective component, hemodiafiltration (HDF)
provides higher clearance of middle molecular solutes com-
pared with low- or high-flux hemodialysis (HD) [1], and may
plausibly improve clinical outcomes. At present, 18%
(70 000 patients) of all dialysis patients in Europe receive on-
line HDF, with substantially lower rates in Japan (8%; 35 000
patients) and no use in the USA [2]. This large variation across
countries is due in part to differences in regulatory approval for
online production of replacement fluid and other technique-
related issues (relative complexity, cost, safety concerns).
Another major reason is the lack of definitive evidence demon-
strating the superiority of HDF. Several studies, including a
prior analysis of Dialysis Outcomes and Practice Patterns Study
(DOPPS) data, have suggested that HDF may result in better
outcomes than HD [3–7], but these findings may be prone to
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residual confounding and selection bias. Results from random-
ized trials were inconclusive, with only one study demonstrat-
ing a survival benefit of HDF versus HD [8–10]. The most
recent French randomized controlled trial (RCT) [11], which
focused on elderly patients, did not find a significant difference
in either all-cause or cardiovascular mortality between HD and
HDF, or between HDF patients with convective volume below
versus above 20 L; post hoc analyses did not identify differences
between the treatments outside of the number of sessions
with asymptomatic hypotension. Further, results may not be
applicable to ‘average’ dialysis patients, due to rigorous inclu-
sion/exclusion criteria in the study design. Based on these con-
siderations, we revisited the association of HDF with mortality
in a ‘real-world’ setting using a more recent DOPPS cohort that
reflects current application of HDF in clinical practice.
MATERIALS AND METHODS
Data source
The DOPPS is an international prospective cohort study of
patients aged 18 years or older treated with in-center HD or
HDF. Patients were randomly selected from national samples
of dialysis facilities within each country [12, 13]. In this analysis,
data from participants in seven European countries (Belgium,
France, Germany, Italy, Spain, Sweden and the UK) in DOPPS
Phase 4 (2009–11) and Phase 5 (2012–15) were used. Data on
demographics, comorbid conditions, laboratory values and pre-
scriptions were abstracted from medical records using uniform
and standardized data collection tools. Mortality events were
collected during study follow-up. Among 11 885 potential sub-
jects, we excluded patients with vintage<90 days, not dialyzing
three times per week, missing type of dialysis (HDF versus HD)
and with no follow-up; 8567 patients remained eligible and
were used in our analysis. In a separate analysis, DOPPS 2014
Medical Director Survey (MDS) data from 92 facilities across
these seven European countries were used to summarize re-
sponses to the question, ‘To what extent do you consider the
following clinical conditions to be indications for HDF or
hemofiltration in your facility?’ for 12 patient characteristics.
Defining HDF
Two separate variables were abstracted from the DOPPS
medical questionnaire: (i) whether the patient was receiving
HDF and (ii) if so, how many liters of intravenous replacement
fluid were prescribed: <4.0 L, 4.0–8.0 L, 8.1–15.0 L, 15.1–20.0 L,
20.1–30.0 L or >30.0 L. We prioritized the latter question, cate-
gorizing a patient with at least 4.0 L of replacement fluid volume
as HDF and <4.0 L as HD. If fluid replacement volume was
missing, then the former question was used to define HDF
versus HD, resulting in some patients classified as HDF but
missing replacement fluid volume. Patients missing data on
both variables were excluded. For analysis, replacement fluid
volume categories were condensed into three groups to avoid
sparse cells: 4.0–15.0 L, 15.1–20.0 L and >20.0 L. Facility per-
centage of patients on HDF (any volume> 4 L) was calculated
for facilities with more than five eligible patients. Regarding
HD, patient-level data on high versus low-flux were not
available in this cohort. However, responses from the 2014
MDS among European DOPPS facilities indicated that high-
flux HD was used for the majority of patients in85% of facili-
ties, including 70% of facilities where high-flux HD was used
for all or almost all patients. These survey data suggest that our
reference group of HD patients was primarily using high-flux
HD.
Statistical analysis
We used Cox regression to estimate the association between
HDF (versus HD) and all-cause mortality. All models were
stratified by DOPPS phase and country, and accounted for fa-
cility clustering using robust sandwich covariance estimators.
Models were progressively adjusted for the following potential
confounders: age, sex, dialysis vintage, 13 summary comorbid-
ities (listed in Table 1), vascular access, blood flow rate, body
mass index (BMI), serum albumin and hemoglobin. Time at
risk started at study enrollment and ended at the time of death,
7 days after leaving the facility due to transfer or change in kid-
ney replacement therapy modality, loss to follow-up, trans-
plantation or end of study phase (whichever event occurred
first).
Similar models were used to assess the association between
HDF and cause-specific mortality: cardiovascular-related mor-
tality and infection-related mortality. In addition to analyzing
any HDF versus HD, we also investigated differences by HDF
replacement fluid volume; HD was treated as the reference and
hazard ratios (HRs) and 95% confidence intervals (CIs) were
estimated for three groups of HDF: 4–15 L, 15.1–20 L and
>20 L. We also tested effect modification by six factors: con-
gestive heart failure, catheter use, albumin (4 versus<4 g/dL),
age (>70 versus70 years), sex and diabetes.
Due to the observational nature of this study, covariate ad-
justment for a wide set of covariates may not account for all of
the differences between HDF and HD patients; we thus provide
an alternate approach utilizing practice differences between
DOPPS facilities. To avoid the treatment-by-indication bias re-
sulting from patients being selected as good candidates for HDF
within each facility, we divided facilities into four groups based
on their propensity to prescribe HDF to patients. Among the
258 facilities with more than five eligible patients, 30% did not
prescribe HDF to any patients, 27% prescribed HDF to 1–14%
of patients, 24% prescribed HDF to 15–49% of patients and
19% prescribed HDF to at least 50% of patients. Because con-
founding is more likely at the facility level than at the patient
level in this model, we additionally adjusted for five facility-
level covariates likely associated with mortality: the percentage
of patients in a facility with a catheter, with single-pool Kt/V
(spKt/V) <1.2, with albumin <3.5 g/dL and with phosphorus
5.5mg/dL, and mean within-facility hemoglobin level. We
performed a sensitivity analysis assessing patient-level HDF
and mortality after excluding the 30% of facilities that did not
prescribe HDF to any patients. We also performed a sensitivity
analysis excluding HDF patients for which post-dilution could
not be confirmed as the typical location used for replacement
fluid by DOPPSMDS data.
2 F. Locatelli et al.Downloaded from https://academic.oup.com/ndt/advance-article-abstract/doi/10.1093/ndt/gfx277/4432201
by Ghent University user
on 14 March 2018
Missing covariate values were addressed by multiple im-
putations using the Sequential Regression Multiple
Imputation Method [14] by IVEware [15]. Results from 20
such imputed datasets were combined for the final analysis
using Rubin’s formula [16]. The proportion of missing data
was <5% for all model covariates, with the exception of albu-
min (12%), BMI (8%) and blood flow rate (6%). All analyses
were conducted using SAS, version 9.4 (SAS institute, Cary,
NC, USA).
RESULTS
HDF use
Our study sample included 20HD facilities from each of
the seven European DOPPS countries, for a total of 135 dialysis
facilities in DOPPS Phase 4 and 128 in DOPPS Phase 5; 8567
patients were included, of whom 2012 (23%) were on HDF. We
observed wide variation in the proportion of patients prescribed
HDF across facilities (Figure 1). A handful of sampled facilities
(6%) across these countries prescribed HDF to all of their pa-
tients, while 30% did not prescribe HDF at all. Figure 2 shows
that in recent years (Phase 5: 2012–15), HDF use was most
common in Sweden (52%) and least common in Germany
(13%). Low-volume HDF (4–15 L replacement fluid, including
acetate-free biofiltration) was fairly common in Italy and the
UK, but in the three countries with the greatest HDF usage
(Sweden, France and Belgium), nearly all HDF patients had
>15 L replacement fluid volume.
Patient characteristics
Among 2012 HDF patients, replacement fluid volume was
4–15 L for 314 patients (16%), 15.1–20 L for 538 patients (27%)
and >20 L for 1010 patients (50%) [including 279 with >30L
(14%)]. Information on replacement volume was missing for
Table 1. Patient characteristics by HDF use and replacement ﬂuid volume
All patients HD All HDF HDF HDF HDF
4.0–15.0L 15.1–20.0L >20.0L
Number of patients 8567 6555 2012 314 538 1010
Age (years) 65.86 15.0 66.26 14.9 64.86 15.0 66.86 15.4 65.26 14.7 64.46 15.1
Sex (% male) 61 60 66 56 65 69
Vintage (years) 2.5 (0.8–5.8) 2.3 (0.7–5.4) 3.2 (1.1–7.0) 3.3 (1.1–7.2) 2.9 (1.0–6.1) 3.4 (1.2–7.1)
Residual kidney function (%) 40 42 35 30 31 39
Vascular access (%)
AV ﬁstula 67 65 73 73 70 75
AV graft 6 6 6 6 9 5
Catheter 27 29 21 22 22 20
Achieved blood ﬂow rate (mL/min) 3196 59 3156 58 3336 58 3126 54 3276 54 3426 59
Achieved treatment time (min) 2396 27 2386 26 2436 30 2346 30 2406 26 2496 31
Intradialytic weight loss (%) 2.56 1.5 2.56 1.5 2.56 1.5 2.76 1.6 2.66 1.6 2.56 1.5
BMI (kg/m2) 26.06 5.4 26.06 5.4 26.16 5.6 25.46 5.5 26.36 5.5 26.16 5.7
spKt/V 1.536 0.33 1.506 0.32 1.626 0.34 1.496 0.31 1.636 0.32 1.666 0.34
Albumin (g/dL) 3.736 0.57 3.746 0.57 3.686 0.57 3.686 0.48 3.726 0.61 3.656 0.57
nPCR (g/kg/day) 1.006 0.25 1.006 0.25 1.006 0.23 1.006 0.22 1.016 0.24 1.006 0.24
Phosphorus (mg/dL) 4.96 1.6 5.06 1.6 4.96 1.6 5.06 1.6 4.86 1.7 4.86 1.5
Hemoglobin (g/dL) 11.46 1.4 11.36 1.4 11.56 1.4 11.56 1.3 11.56 1.4 11.56 1.4
Ferritin (ng/mL) 380 (200–601) 377 (200–599) 392 (203–610) 376 (189–546) 399 (193–605) 394 (212–641)
CRP (mg/L) 6.0 (2.9–15.0) 6.0 (2.9–14.6) 5.4 (2.9–15.3) 7.4 (4.0–17.4) 5.5 (2.9–14.9) 5.0 (2.5–15.4)
WBC count (1000 cells/mm3) 7.16 2.3 7.16 2.3 6.96 2.2 7.16 2.1 6.86 2.1 7.06 2.3
Pre-dialysis SBP (mmHg) 137.96 21.9 137.76 21.7 138.46 22.6 136.76 24.3 137.56 22.6 138.96 22.0
Post-dialysis SBP (mmHg) 132.06 22.6 132.16 22.2 132.06 23.9 130.76 23.9 130.46 23.3 132.86 24.2
Transplant waiting list 12 11 13 12 12 13
Comorbid conditions (%)
Coronary artery disease 35 35 36 35 35 38
Cancer (non-skin) 17 17 17 17 16 18
Other cardiovascular disease 31 31 31 31 29 33
Cerebrovascular disease 17 16 17 21 16 18
Congestive heart failure 19 20 16 15 15 17
Diabetes 36 36 37 36 36 38
Gastrointestinal bleeding 5 5 5 4 4 4
Hypertension 86 86 84 81 81 87
Lung disease 14 14 12 15 14 11
Neurologic disease 12 12 10 13 10 9
Psychiatric disorder 17 18 16 13 19 15
Peripheral vascular disease 30 30 32 32 31 33
Recurrent cellulitis, gangrene 9 9 10 10 11 10
Values are presented as mean6 SD or median (interquartile range) or percentage shown; residual kidney function deﬁned as urine output >200 mL/day; intradialytic weight loss
deﬁned as percentage of body weight shown, normalized to midweek; AV, arteriovenous; CRP, C-reactive protein; nPCR, normalized protein catabolic rate; SBP, systolic blood pressure
and WBC, white blood cell.
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150 patients (7%); these patients were included in the primary
analysis of any HDF versus HD but excluded from analyses by
replacement fluid volume. Table 1 displays patient characteris-
tics by replacement fluid volume. Compared with HD, HDF
patients tended to be younger and were more likely to be male,
especially those on the highest volume HDF. HDF patients had
longer dialysis vintage, and were less likely to have residual kid-
ney function or to dialyze with a catheter. Blood flow rate and
Kt/V were higher for HDF patients, particularly for high-vol-
ume HDF. Most laboratory values were comparable between
HDF and HD patients; similarly, the presence of comorbid con-
ditions varied slightly between groups. Intradialytic weight loss
(IDWL) was 2.5% of body weight—equal to 2 L for an 80 kg
patient—among patients on HDF>20 L and so convection vol-
ume (replacement fluid volumeþ IDWL) was approximately
>22 L in this group.
HDF and mortality
Median follow-up was 1.5 years (interquartile range: 0.7–
2.5) and 1988 patients died, resulting in a mortality rate of 14.8
per 100 patient-years. In unadjusted models, only stratified by
DOPPS phase and country (Table 2, Model 1), the HR (95%
CI) of HDF versus HD was 1.01 (0.88–1.16) and the HR (95%
CI) of high volume (>20 L) HDF versus HD was 0.90 (0.75–
1.08). Because of differences in patient characteristics shown in
Table 1, adjustment for confounding factors results in less
biased effect estimates. The adjusted HR (95% CI) was 1.14
(1.00–1.29) for HDF versus HD and 1.08 (0.92–1.28) for HDF
>20 L versus HD (Table 2, Model 5). In a sensitivity analysis
excluding 30% of facilities that did not prescribe HDF to any
patients, we observed an HR (95% CI) of 1.11 (0.98–1.26) for
HDF versus HD. We found no evidence of effect modification
by congestive heart failure, catheter use, albumin, sex or dia-
betes (P for interaction>0.3). The HR (95% CI) for HDF versus
HD was 1.23 (1.06–1.43) among age >70 years and 0.99 (0.82–
1.19) among age70 years (P for interaction¼ 0.05).
In similarly adjusted models analyzing cardiovascular-
related mortality (n¼ 758 events; 9% of patients) and infection-
related mortality (n¼ 330 events; 4% of patients), we observed
an HR (95% CI) for HDF versus HD of 1.20 (1.01–1.43) and
1.14 (0.83–1.56), respectively.
In an additional analysis using facility percentage of patients
prescribed HDF as the exposure, with facilities that do not pre-
scribe HDF to any patients as the reference group, the adjusted
HR (95% CI) was 1.17 (1.00–1.37) for facilities prescribing
HDF to 1–14% of patients, 1.09 (0.92–1.30) for facilities pre-
scribing HDF to 15–49% of patients and 1.31 (1.08–1.57) for
FIGURE 1: Dialysis facility use of HDF, by country and DOPPS
phase. DOPPS Phase 4: 2009–11; DOPPS Phase 5: 2012–15. Data
suppressed from ﬁve facilities with sparse data (ﬁve or fewer eligible
patients).
FIGURE 2: HDF replacement ﬂuid volume, by country and DOPPS
phase. DOPPS Phase 4: 2009–11; DOPPS Phase 5: 2012–15.
Table 2. HDF and all-cause mortality, by level of adjustment
Model 1 Model 2 Model 3 Model 4 Model 5
Stratified by phase
and country
þAge, sex, vintage þ13 summary
comorbidities
þVascular access,
blood flow rate
þBMI, Hgb,
albumin
Overall
Any HDF versus HD 1.01 (0.88–1.16) 1.08 (0.95–1.23) 1.09 (0.97–1.24) 1.14 (1.01–1.29) 1.14 (1.00–1.29)
By volume replacement
HD (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.) 1 (Ref.)
HDF, 4.0–15.0 L 1.35 (1.05–1.74) 1.30 (1.04–1.62) 1.28 (1.03–1.58) 1.28 (1.03–1.58) 1.26 (1.01–1.57)
HDF, 15.1–20.0 L 1.04 (0.86–1.25) 1.09 (0.91–1.31) 1.10 (0.92–1.32) 1.15 (0.96–1.37) 1.16 (0.97–1.40)
HDF, >20.0 L 0.90 (0.75–1.08) 1.00 (0.84–1.19) 1.02 (0.86–1.21) 1.09 (0.92–1.29) 1.08 (0.92–1.28)
Values are presented as HR (95% CI); Hgb, hemoglobin; 13 comorbidities listed in Table 1.
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facilities prescribing HDF to 50% of patients. Results were
consistent when analyzing cardiovascular-related mortality and
infection-related mortality (Table 3). A sensitivity analysis cate-
gorizing facilities by percentage of patients prescribed HDF
>20 L rather than any volume also yielded similar results.
In a sensitivity analysis excluding 597 HDF patients for
whom post-dilution could not be confirmed as the typical loca-
tion used for replacement fluid by DOPPS MDS data (n¼ 218
pre-dilution, n¼ 93 mid or mixed dilution, n¼ 286 missing
MDS data), we observed an adjusted all-cause mortality
HR¼ 1.03 (95% CI 0.85–1.25) comparing HDF >20L versus
HD (adjusted as in Table 2, Model 5).
Nephrologists’ perception on clinical indications for
HDF use
Based on responses to the 2014 DOPPS MDS, nephrologists
indicated which patient characteristics they considered as
‘strong indications’ for HDF use (Table 4). Overall, the most
common indications were dialysis-related amyloidosis (84% of
medical directors), polyneuropathy (77%), hemodynamic in-
stability (75%) and longer life expectancy (74%), but some dif-
ferences were observed across countries; for instance, large
patient size was a clinical indication for HDF in Spain (88% of
medical directors) but not in Germany (8%).
DISCUSSION
The current study of a contemporary cohort of patients across
seven countries found no evidence of a survival benefit with
HDF, even at replacement fluid volumes >20L (convection
volumes above22 L after accounting for2 kg ultrafiltration).
Our findings are in contrast to prior cohort studies that sug-
gested better outcomes for HDF versus HD, including a prior
analysis of DOPPS data [3–7].
In recent years, three RCTs tested the impact of HDF on
mortality [8–10]. However, results of these studies were incon-
sistent, with only one study indicating a survival benefit [10]
although with some methodological drawbacks [17]. Two
meta-analyses [18, 19] of the same RCTs concluded that HDF
resulted in lower mortality, especially among patients receiving
the highest convection volume. One potential explanation for
the discrepancy between results of the meta-analyses and those
from the two RCTs included in the meta-analyses could be that
the majority of patients in these two trials [8, 9] did not reach
the target replacement fluid volume. In the ESHOL trial [10],
the only study showing a positive effect of HDF on survival at
primary analysis, patients were excluded after randomization if
the pre-set 18 L volume of replacement fluid was not reached.
Patients with better vascular access flow and intradialytic car-
diovascular stability, who also tend to be generally healthier,
would be more likely to achieve larger replacement fluid vol-
umes, resulting in a potential selection bias [17].
Three other meta-analyses [20–22] have emphasized im-
portant methodological limitations of the RCTs. Peters et al.
[18] showed better survival in the primary analysis; however,
the secondary analyses considered achieved convection vol-
umes and thus no longer followed the randomization protocol.
Table 3. Facility percentage of HDF use and mortality
Number of facilities (%) All-cause mortality CV-related mortality Infection-related
mortality
Facility percentage of patients using HDF
0% (all HD) 78 (30%) 1 (Ref.) 1 (Ref.) 1 (Ref.)
1–14% 69 (27%) 1.17 (1.00–1.37) 1.33 (1.04–1.72) 1.28 (0.89–1.83)
15–49% 61 (24%) 1.09 (0.92–1.30) 1.11 (0.83–1.47) 1.29 (0.88–1.87)
50% 50 (19%) 1.31 (1.08–1.57) 1.37 (1.03–1.81) 1.31 (0.85–2.01)
Values are represented as HR (95% CI); Cox models stratiﬁed by DOPPS phase and country, adjusted for age, sex, vintage, 13 comorbidities (listed in Table 1), vascular access, blood
ﬂow rate, BMI, serum albumin, hemoglobin and ﬁve facility-level characteristics: percentage of patients in a facility with a catheter, with spKt/V<1.2, with albumin<3.5 g/dL and with
phosphorus 5.5mg/dL, and mean within-facility hemoglobin level; n¼ 8549 patients from 258 facilities (ﬁve facilities with less than or equal to ﬁve eligible patients excluded). CV,
cardiovascular.
Table 4. Nephrologists’ perception on clinical indications for HDF usea
Patient characteristic All Belgium France Germany Italy Spain Sweden UK
Dialysis-related amyloidosis (%) 84 86 100 67 73 94 88 82
Polyneuropathy (%) 77 79 80 67 73 100 75 65
Hemodynamic instability (%) 75 57 100 50 82 88 81 76
Longer life expectance (%) 74 64 100 33 73 100 81 71
Has been on dialysis 10 years (%) 63 50 80 25 27 82 81 82
Heart failure (%) 58 50 60 42 64 82 56 47
Has been on dialysis 5 years (%) 58 50 80 17 27 71 69 82
Worsening nutritional status (%) 55 43 100 25 55 100 38 47
Coronary artery disease (%) 51 36 80 33 55 76 56 35
Diabetes (%) 51 36 80 25 64 76 50 41
Large patient size (%) 49 57 40 8 27 88 38 59
Elderly (%) 28 21 40 25 18 35 25 35
aAs reported by medical directors at DOPPS facilities in Phase 5 (2014) MDS; n¼ 92 medical directors surveyed: 14 in Belgium, 5 in France, 12 in Germany, 11 in Italy, 17 in Spain, 16
in Sweden and 17 in the UK; the proportion of medical directors in each country who indicated that the given patient characteristic was a ‘strong indication’ for HDF is reported.
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As RCT data outside of the context of randomization are con-
sidered to reach only observational evidence levels with insuffi-
cient data on potential confounders, their conclusions should
be interpreted with caution.
Along with these methodological limitations, the most
plausible explanation for the discrepancies between our find-
ings and those of the meta-analysis of Peters et al. [18] is the
substantial difference in study populations due to stringent in-
clusion/exclusion criteria of the trials considered by Peters et al.
[18]. Conversely, the DOPPS design [12, 13] results in samples
of dialysis facilities and patients who are representative of prac-
tices as implemented in each country. Hence, results of this ana-
lysis may be more relevant to ‘real-world’ HD patients
compared with those of clinical trials.
Our results are consistent with the Nistor et al. [20] meta-
analysis and Siriopol et al. [5] study, which did not find any re-
lation between high convection volumes and survival.
Additionally, Buchanan et al. [23], using functional magnetic
resonance imaging (fMRI), found no difference in cardiac wall
motion abnormalities for HDF versus HD. In contrast to the
secondary analyses of randomized trials [8, 9] and the Peters
et al. [18] meta-analysis, we did not find any survival benefit
from HDF even among patients with the highest convection
volume. Patient selection for trial participation may have con-
tributed to this discrepancy, since only ‘healthier’ patients (e.g.
those with permanent vascular access, able to deliver higher
blood flows) could reach the high convection volumes of HDF.
The positive effect of higher convection volumes may not apply
to an overall dialysis population such as the one assessed in the
present study, since usually only healthier patients with good
cardiovascular status are able to reach and tolerate the high
convection volumes.
Physicians’ attitudes toward HDF use and its indications
vary widely across countries, again reflecting the uncertainty
surrounding the potential benefits of this technique. Along with
complications from long time on dialysis (e.g. amyloidosis),
longer life expectancy was one of the most common indications
reported by medical directors, which suggests the possibility
that HDF patients may be overall healthier compared with HD
patients. This indication suggests an important patient selection
and a potentially strong confounder that would favor better
outcomes for HDF.
Our study has some strengths and weaknesses. Strengths
include detailed data collection on potential confounders and
causes of death. The variation in facility practice patterns allowed
the facility percentage HDF use to be used as an exposure vari-
able in secondary analyses, reducing treatment-by-indication
bias. Compared with the previous DOPPS analysis [3], which
showed seemingly conflicting results, the current study had a
much larger sample size, a larger proportion of patients using
high-volume HDF and a more contemporary cohort where the
quality of HD care has improved. Therefore, the current study
provides a more accurate representation of clinical practices in a
contemporary care setting. One limitation of our study is that
follow-up began at DOPPS entry rather than at initiation of HDF
because information on the exposure prior to DOPPS entry was
not available. Thus, patients for whom HDF was discontinued
due to ineffectiveness or other reasons prior to DOPPS entry
were misclassified as HD in the analysis. In addition, due to the
observational nature of the DOPPS, it is possible that model ad-
justment failed to adequately account for selected confounders so
that residual confounding may remain and affect our findings.
However, because patients prescribed HDF tended to be slightly
younger and healthier, each of these limitations would more
likely bias results toward an HDF benefit. On the other hand, we
were unable to account for intradialytic hemodynamic instabil-
ity—an indication for HDF as shown in Table 4—in our models,
which may result in bias in the opposite direction.
In conclusion, our analyses of current dialysis practices do
not support the wide spread notion that HDF, especially with
high convection volume, provides superior patient survival,
hence supporting the equipoise of HDF and HD. Further trials
specifically designed to test the effect of different convection
volumes on clinical outcomes are needed in order to adequately
inform clinical practices.
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